{"disease":{"id":"atopic-dermatitis-ad","name":"atopic dermatitis ad"},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Refractory, moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older not adequately controlled with other systemic therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"abrocitinib-200-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 200 mg","generic_name":"abrocitinib-200-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-suspension-f1","indication_name":"Moderate to severe atopic dermatitis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F1","generic_name":"abrocitinib-suspension-f1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":33,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-suspension-f6","indication_name":"Moderate to severe atopic dermatitis in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib Suspension F6","generic_name":"abrocitinib-suspension-f6","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"tofacitinib-xeljanz","indication_name":"Atopic Dermatitis (AD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tofacitinib (Xeljanz)","generic_name":"tofacitinib-xeljanz","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK3","drug_class":"Janus Kinase Inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":12,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05084417","title":"A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"OM1, Inc.","has_results":false},{"nct_id":"NCT04541810","title":"A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":2369,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07276620","title":"Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT05928169","title":"Determinants of Chronic Inflammatory Skin Disease Trajectories","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University Hospital Schleswig-Holstein","has_results":false},{"nct_id":"NCT07021495","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","phase":"","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT05330637","title":"Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT06599411","title":"Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":700,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04173442","title":"Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy","phase":"","overall_status":"COMPLETED","enrollment_count":581,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07316465","title":"Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Universitair Ziekenhuis Brussel","has_results":false},{"nct_id":"NCT07180511","title":"A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":460,"lead_sponsor_name":"E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT07185282","title":"A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":375,"lead_sponsor_name":"Minghui Pharmaceutical (Hangzhou) Ltd","has_results":false},{"nct_id":"NCT06631170","title":"Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05667623","title":"To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Otsuka Beijing Research Institute","has_results":false},{"nct_id":"NCT07438509","title":"Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":270,"lead_sponsor_name":"Jinnah Postgraduate Medical Centre","has_results":false},{"nct_id":"NCT05650320","title":"To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"Otsuka Beijing Research Institute","has_results":false},{"nct_id":"NCT07105488","title":"A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Bluefin Biomedicine, Inc.","has_results":false},{"nct_id":"NCT07046039","title":"The Impact of Untreated Depression and Anxiety Among Patients With Skin Diseases in Jeddah, Saudi Arabia.","phase":"","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"King Abdulaziz University","has_results":false},{"nct_id":"NCT07175233","title":"A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":184,"lead_sponsor_name":"Jiangsu Simcere Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06810050","title":"Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"CAGE Bio Inc.","has_results":false},{"nct_id":"NCT07182864","title":"MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Minghui Pharmaceutical (Hangzhou) Ltd","has_results":false},{"nct_id":"NCT04772885","title":"A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"Kymera Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06996912","title":"A Study for HSK44459 in Participants With Atopic Dermatitis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Xizang Haisco Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06503536","title":"A Study to Assess Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization in Chinese Participants Receiving Upadacitinib for Atopic Dermatitis (AD) Through Chart Review","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07186387","title":"Study of LW402 in Moderate-to-Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT05456529","title":"Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03198390","title":"Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions","phase":"","overall_status":"TERMINATED","enrollment_count":100,"lead_sponsor_name":"University of Arizona","has_results":false},{"nct_id":"NCT07323719","title":"Comparison Between Topical N-acetyl Cysteine (NAC) in Cold Cream Versus Cold Cream in Mild and Moderate Atopic Dermatitis: Clinical and Bacteriological Evaluation. A Randomized Control Trial.","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT07235384","title":"A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT06855745","title":"Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Alphyn Biologics","has_results":false},{"nct_id":"NCT03389893","title":"Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":72,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT06723405","title":"Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Evommune, Inc.","has_results":false},{"nct_id":"NCT06850311","title":"Herbal Ointment in Treating Atopic Dermatitis Topically","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"En Chu Kong Hospital","has_results":false},{"nct_id":"NCT03168113","title":"Atopic Dermatitis (AD) and Food Allergy","phase":"","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT07103174","title":"A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Shanghai Mabgeek Biotech.Co.Ltd","has_results":false},{"nct_id":"NCT06361992","title":"Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Catalysis SL","has_results":false},{"nct_id":"NCT03151148","title":"Targeted Microbiome Transplant in Atopic Dermatitis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT01979016","title":"Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT06982352","title":"Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"LAPIX Therapeutics Inc.","has_results":false},{"nct_id":"NCT04246372","title":"Tofacitinib for Immune Skin Conditions in Down Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"University of Colorado, Denver","has_results":true},{"nct_id":"NCT04520308","title":"An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Eric Simpson","has_results":false},{"nct_id":"NCT07194421","title":"In-Use Tolerance & Efficacy Study Under Dermatological Control of Sunscreen in Adults With Atopic Dermatitis Skin","phase":"","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Pierre Fabre Dermo Cosmetique","has_results":false},{"nct_id":"NCT07301658","title":"Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis.","phase":"NA","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"i+Med S.Coop.","has_results":false},{"nct_id":"NCT05372653","title":"A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Otsuka Pharmaceutical Co., Ltd.","has_results":true},{"nct_id":"NCT06920693","title":"Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Generate Biomedicines","has_results":false},{"nct_id":"NCT07146971","title":"Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Good Molecules, LLC","has_results":false},{"nct_id":"NCT04056130","title":"A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"KoBioLabs","has_results":false},{"nct_id":"NCT07066150","title":"A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement","phase":"NA","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Shanghai Chicmax Cosmetic Co., Ltd.","has_results":false},{"nct_id":"NCT07503197","title":"A Pilot Study on the Efficacy of 2% Cholesterol Cream in Preventing Transepidermal Water Loss and Clinical Symptoms in Mild to Moderate Atopic Dermatitis","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30,"lead_sponsor_name":"Institute of Dermatology, Thailand","has_results":false},{"nct_id":"NCT07113366","title":"Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Kaohsiung Veterans General Hospital.","has_results":false},{"nct_id":"NCT06931990","title":"A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}